• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Patent Filing Change ImmunityBio Stock Narrative

    Simply Wall St·09/13/2026 21:17:20
    Listen to the news
    • ImmunityBio recently filed a patent application outlining broader potential uses for Anktiva and reported lung cancer data where patients with less severe lymphocyte depletion recorded a median survival of 21.1 months versus 11.5 months for those with more severe depletion, ahead of presentations at the World Conference on Lung Cancer and the H.C. Wainwright conference.
    • The focus on lymphocyte depletion and survival outcomes positions ImmunityBio's Anktiva platform squarely around immune system health, which is central to its broader oncology and immune disorder pipeline.
    • We will now examine how ImmunityBio's new Anktiva patent push and survival data could shape the broader investment narrative around its pipeline.

    Compare ImmunityBio's immune focused thesis with a hand picked group of oncology and biotech opportunities screened for resilient balance sheets and fundamentals via the list of solid balance sheet and fundamentals (23 results).

    ImmunityBio Investment Narrative Recap

    To own ImmunityBio, investors need to believe ANKTIVA can expand beyond bladder cancer and that the wider immune focused platform converts into multiple approved uses over time. The recent patent filing and lung cancer survival data support that broader immune thesis but do not change the reality that ANKTIVA remains heavily concentrated in a single commercial indication today.

    The most important near term catalyst still sits in regulatory and clinical progress for new ANKTIVA indications and combinations. The biggest risk remains execution against an ambitious trial slate while ImmunityBio carries losses and negative equity. If timelines stretch or regulators demand more data, funding needs and dilution risk could rise.

    Among recent disclosures, the focus on ANKTIVA’s effect in patients with different levels of lymphocyte depletion is the most relevant to this update. It links back to ImmunityBio’s stated goal of addressing lymphopenia in oncology and potentially beyond cancer, tying clinical results to a much wider addressable patient pool if future studies support that direction.

    For catalysts, that immune health angle matters. It interacts directly with existing programs in checkpoint inhibitor failure, recombinant BCG and cell therapies, which are already expected to influence revenue and earnings trajectories. The same work also sharpens risk. If future trials in lymphopenia or prevention settings do not show clear benefit, the business could remain reliant on bladder cancer for longer.

    ImmunityBio's current analyst narrative points to revenues of US$1.6b and earnings of US$673.2m by 2029, based on a forecast yearly revenue expansion rate of 125.9%. This implies a move from a loss of US$854.5m in earnings today to US$673.2m. This is an earnings swing of about US$1.53b over that period.

    Uncover why ImmunityBio's fair value indicates a 64% potential upside to its current price that may not last much longer.

    NasdaqGS:IBRX 1-Year Stock Price Chart
    NasdaqGS:IBRX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate lens on ImmunityBio puts clinical risk in the spotlight rather than the new lung cancer survival data. That bearish group already assumed earnings of about US$719.9m on roughly US$1.7b of revenue by 2029. These expectations were set before this news, so views on upside or downside could shift sharply.

    Explore 4 other ImmunityBio fair value estimates, including one that suggests it could be worth just $12.00!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more ImmunityBio sized ideas?

    If the ImmunityBio story has sharpened your thinking about risk, reward and balance sheets, the next step is to widen your opportunity set using the Simply Wall St Screener.

    • For investors who want resilient businesses with room to run, start with a 15 high quality undiscovered gems that combine strong fundamentals with lower market attention.
    • If capital preservation and steadier profiles matter most to you, filter for 11 resilient stocks with low risk scores that score well on financial strength and volatility.
    • Income focused readers can concentrate on reliable cash payers by zeroing in on 6 dividend fortresses that aim to pair higher yields with solid backing.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.